Aims: Although laparoscopic splenectomy (LS) for benign hematologic disease is well accepted, its role in the treatment of haematological malignancies is still controversial. The aim of this study is to compare efficacy and feasibility of LS for hematologic malignancies and patients outcome with benign disease patients wgo underwent thesame procedure.Methods: Between January 2001 and December 2007 in two affiliated university hospital 141 patients underwent to LS for hematologic disease. 104 for benign hematologic disorders (HB) and 37 (26,2%) for malignancies (HM). Results: Median splenic weight was greater in the HM group (mean 787 gr range 205-2500 gr) than in the HB group (mean 350 ge range 150-110 gr) with a statistically significant difference (p<0.005). The conversion rate is significantly greater in the HM group (22,2% versus 2,9% p<0.001) instead the mean operation time (150 minutes in HM group vs 125 in HB) and the mean blood loss are similar in the two groups of patients. Considering the postoperative course, morbidity (13.8% in HM vs 11,5% in HB group) and mean hospital stay (5,5 days in HM vs 4,4 in HB) were not different among the two groups. No mortality occurred.Conclusions: The analysis of our data highlights that LS for hematologic malignancies is effective and feasible even if associated to a higher conversion rate compared with LS for benign disorders. Besides, no differences in the outcome of patients (blood loss, morbidity, mortality and hospital stay) was noted among the two groups
LAPAROSCOPIC SPLENECTOMY IN HEMATOLOGIC MALIGNANCIES / Gelmini, Roberta; F., Romano; Franzoni, Chiara; G., Piacentini; Gambini, Anna; C., Penati; Saviano, Massimo; F., Uggieri. - ELETTRONICO. - 1:(2009), pp. 1-1. (Intervento presentato al convegno SAGES 2009 Annual Meeting tenutosi a Phoenix USA nel April 22-25, 2009).
LAPAROSCOPIC SPLENECTOMY IN HEMATOLOGIC MALIGNANCIES
GELMINI, Roberta;FRANZONI, Chiara;GAMBINI, Anna;SAVIANO, Massimo;
2009
Abstract
Aims: Although laparoscopic splenectomy (LS) for benign hematologic disease is well accepted, its role in the treatment of haematological malignancies is still controversial. The aim of this study is to compare efficacy and feasibility of LS for hematologic malignancies and patients outcome with benign disease patients wgo underwent thesame procedure.Methods: Between January 2001 and December 2007 in two affiliated university hospital 141 patients underwent to LS for hematologic disease. 104 for benign hematologic disorders (HB) and 37 (26,2%) for malignancies (HM). Results: Median splenic weight was greater in the HM group (mean 787 gr range 205-2500 gr) than in the HB group (mean 350 ge range 150-110 gr) with a statistically significant difference (p<0.005). The conversion rate is significantly greater in the HM group (22,2% versus 2,9% p<0.001) instead the mean operation time (150 minutes in HM group vs 125 in HB) and the mean blood loss are similar in the two groups of patients. Considering the postoperative course, morbidity (13.8% in HM vs 11,5% in HB group) and mean hospital stay (5,5 days in HM vs 4,4 in HB) were not different among the two groups. No mortality occurred.Conclusions: The analysis of our data highlights that LS for hematologic malignancies is effective and feasible even if associated to a higher conversion rate compared with LS for benign disorders. Besides, no differences in the outcome of patients (blood loss, morbidity, mortality and hospital stay) was noted among the two groups
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
